Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease | MicrobiomeTrials← Back to trialsNCT05854615
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2024-01-01Est. Completion: 2027-10
Enrollment target: 3 participants Locations- Hospital Canselor Tunku Mukhriz, Kuala Lumpur, Malaysia
Other microbiome trials you might be interested in
Peripheral Vascular Disease
Abstract:
It is intuitive that post discharge surgical complications are associated with increased patient dissatisfact…
Multiple LocationsCompleted Jul 2017
Cardiac ArrestOut-of-hospital Cardiac Arrest (OHCA)
Out-of-hospital cardiac arrest is a public health problem for which overall survival is below 10%. Post-cardiac arrest s…
Montpellier, FranceEst. completion Mar 28, 2028
Ischemic StrokeAtrial Fibrillation
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major c…
Bruges, BelgiumEst. completion Jan 1, 2028